Clinical Trial Update: Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of ProTmune for allogeneic hematopoietic cell transplantation in adults with hematologic malignancies completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Graft-versus-host Disease
• Hematologic Malignancies
• Myelodysplastic Syndromes
• Myelogenous Leukemia

Drugs mentioned

• ProTmune

Snippet

Sponsor: Fate Therapeutics | Conditions: Hematologic Malignancies, Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-02-08